HOUSTON--(BUSINESS WIRE)--Dabaghi Therapeutics, Inc., a stem cell and gene therapy pioneer, announced today plans for the world’s first Human Cord Blood (HCBC) stem cell treatment clinical trial via Intramyocardial delivery. The Phase 1 clinical trial, expected to take place in Brasil, will demonstrate the feasibility and safety of intra-operative, intra-myocardial injection of HLA-crossmatched CD133+ HCBCs in adults with dilated cardiomyopathy associated with impaired left ventricular function. The trial plans to assess the feasibility and safety of a novel approach to therapeutic angiogenesis and myocyte regeneration in patients referred with heart failure who are not likely to improve with conventional medical treatment.
